^
Association details:
| Biomarker: | EGFR L858R + RBM10 Q255* |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer
Excerpt:
...we used the BH3 mimetic Bcl-xL inhibitor navitoclax (ABT-263) which binds with high affinity to Bcl-xL (43), in combination with osimertinib and observed decreased viability with enhanced PARP cleavage and Caspase 3 and 7 activity in two independent RBM10-deficient EGFR mutant cell lines (A014 – EGFR L858R; RBM10 Q255* and H1975 – EGFR L8585R/T790M; RBM10 G840fs*7)...
DOI:
10.1101/2020.10.26.356352
